Mylan (Nasdaq: MYL) reported earnings on Feb. 21. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Mylan missed slightly on revenues and beat expectations on earnings per share.

Compared with the prior-year quarter, revenue expanded and GAAP earnings per share grew.

Margins increased across the board.

Revenue details
Mylan recorded revenue of $1.53 billion. The 16 analysts polled by S&P Capital IQ anticipated sales of $1.56 billion on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $1.43 billion.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.53. The 21 earnings estimates compiled by S&P Capital IQ anticipated $0.50 per share on the same basis. GAAP EPS of $0.30 for Q4 were much higher than the prior-year quarter's $0.00 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 42.1%, 170 basis points better than the prior-year quarter. Operating margin was 17.5%, 220 basis points better than the prior-year quarter. Net margin was 8.5%, 710 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $1.62 billion. On the bottom line, the average EPS estimate is $0.53.

Next year's average estimate for revenue is $6.87 billion. The average EPS estimate is $2.40.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 543 members out of 577 rating the stock outperform, and 34 members rating it underperform. Among 178 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 175 give Mylan a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mylan is outperform, with an average price target of $26.00.

The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Mylan the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.